News NEJM responds to claims of bias from Justice Department The New England Journal of Medicine (NEJM) has hit back at assertions of bias in its editorial policies from Republican activist Edward Martin Jr.
News Eisai's full lecanemab phase 3 trial results for Alzheimer's... Following the news of two lecanemab-related deaths reported on the eve of the C
News UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face